Different Methods Used for in Vitro Antihypertensive Activity of Leaf Extract of Codiaeum variegatum

Abstract

Hypertension remains one of the most significant global health challenges, affecting over 1.3 billion people worldwide and contributing to increased risks of cardiovascular, renal, and cerebrovascular complications (World Health Organization [WHO], 2023). Current synthetic antihypertensive drugs such as angiotensin-converting enzyme (ACE) inhibitors, calcium-channel blockers, and ?-blockers, though effective, are often associated with adverse effects and limited accessibility in developing countries. Consequently, plant-based antihypertensive research has gained momentum as a safer and more sustainable alternative. Codiaeum variegatum (L.) Blume (Euphorbiaceae), commonly known as garden croton, has been reported for multiple pharmacological effects, including antioxidant, anti-inflammatory, antimicrobial, and cardiovascular activities. Its leaves contain an abundance of flavonoids, phenolics, and terpenoids that are hypothesized to exhibit ACE-inhibitory and vasodilatory actions. This review summarizes the various in vitro methods used to evaluate the antihypertensive potential of C. variegatum leaf extract, focusing on ACE inhibition, renin inhibition, nitric-oxide release, calcium-channel modulation, and antioxidant-linked assays. Analytical techniques, result interpretations, advantages, and limitations of each assay are critically discussed. The review also explores correlations with in vivo and in silico studies, providing insights into mechanistic understanding and methodological standardization. The findings suggest that C. variegatum leaf extract demonstrates potent in vitro ACE inhibition and free-radical scavenging activities, reinforcing its potential as a natural antihypertensive agent.

Keywords

Introduction

Phytochemical class	Representative compounds	Probable mechanism of action	References
Flavonoids	Quercetin, Rutin	ACE inhibition, NO release	Lee et al., 2019
Phenolic acids	Gallic, Caffeic acid	Antioxidant, endothelial protection	Kumar et al., 2022
Terpenoids	Lupeol, β-amyrin	Calcium-channel modulation	Reddy et al., 2017
Saponins	Polygalacin D	Diuretic effect and vasorelaxation	Patel et al., 2022

Fig no.1: High-quality photograph of Codiaeum variegatum leaf showing variegated structure (botanical source).

Fig no.2: Schematic diagram showing ACE inhibition assay mechanism (HHL → Hippuric acid + His-Leu).

Fig no. 3: Diagram linking oxidative stress to hypertension pathways with antioxidant intervention.

7. Advantages and Limitations of In Vitro Methods

Advantages:

In vitro models provide a controlled and reproducible platform for evaluating the antihypertensive potential of plant extracts before proceeding to animal or clinical trials. These assays are rapid, cost-effective, and require minimal sample quantities, allowing simultaneous screening of multiple extracts or bioactive fractions under standardized conditions (Lee et al., 2019; Bhandari & Chaudhary, 2023). One of the principal advantages is the mechanistic specificity of in vitro assays. For instance, the angiotensin-converting enzyme (ACE) inhibition test directly evaluates a critical enzymatic step in the renin–angiotensin–aldosterone system (RAAS), enabling researchers to determine the precise inhibitory capacity of phytochemicals such as flavonoids, phenolic acids, and peptides (Anand et al., 2021). Similarly, renin inhibition assays help identify compounds acting upstream in the cascade, offering complementary mechanistic data. In vitro systems also facilitate quantitative comparison of activity through parameters such as IC?? or Ki values, which are valuable for structure–activity relationship (SAR) studies (Sharma & Joshi, 2021). Analytical tools like HPLC, LC–MS/MS, and fluorometric assays enhance precision, enabling researchers to evaluate small biochemical changes in enzyme kinetics or substrate conversion rates. Another major strength lies in ethical and logistical considerations. Since in vitro tests eliminate the need for live animal use in the initial screening stage, they adhere to the 3Rs principle (Replacement, Reduction, and Refinement) of experimental ethics, aligning with global regulatory expectations (WHO, 2023). These assays can also be conducted in high-throughput formats, which support rapid screening of large plant libraries and bioactive compound collections. Furthermore, in vitro models enable correlative exploration with in silico molecular docking, allowing prediction of enzyme–ligand interactions and validation of experimental outcomes (Ahmed et al., 2021; Tripathi & Singh, 2021). This integrative approach significantly enhances research efficiency and accelerates the discovery pipeline for novel antihypertensive agents derived from medicinal plants such as Codiaeum variegatum. These methods are rapid, economical, and require small sample volumes while allowing screening of multiple extracts under controlled conditions (Lee et al., 2019).

LIMITATIONS:

Despite their advantages, in vitro assays possess several critical limitations that restrict their direct translation to physiological and clinical contexts. The primary limitation is the absence of complex biological interactions that occur within a living system. In vitro enzyme or cell-based models do not replicate the intricate physiological environment of blood pressure regulation involving neurohormonal feedback loops, vascular tone, renal filtration, and metabolic clearance (Fuchs et al., 2022). Another significant limitation is the lack of pharmacokinetic and bioavailability data. Compounds exhibiting potent ACE or renin inhibitory activity in vitro may fail in vivo due to poor absorption, rapid metabolism, or limited systemic distribution (Zhang & Li, 2021). Moreover, plant extracts are complex mixtures containing multiple secondary metabolites, and their interactions—synergistic or antagonistic—are not adequately reflected in simplified in vitro systems (Sharma & Joshi, 2021). Variability in extraction procedures, solvent types, pH conditions, enzyme sources, and substrate specificity can lead to inconsistent results across laboratories (Mahato & Das, 2020). For instance, crude plant extracts often contain pigments or phenolics that interfere with spectrophotometric readings, causing false-positive or non-specific inhibition signals. This necessitates appropriate assay validation, including blank corrections, positive controls (such as captopril or aliskiren), and repeatability testing (Smith & Brown, 2021). Furthermore, enzyme inhibition observed in vitro does not guarantee systemic blood pressure reduction in vivo, as the biological targets may be inaccessible or regulated differently under physiological conditions (Rahman & Ali, 2021). Many compounds may also undergo biotransformation into inactive metabolites after oral administration, reducing their therapeutic efficacy. Another constraint involves standardization and reproducibility. Lack of harmonized assay protocols and reporting formats hinders meta-analyses and cross-study comparisons. Researchers often employ varying substrate concentrations, incubation times, and detection wavelengths, resulting in data heterogeneity (Kaur & Singh, 2023). Lastly, while in vitro models provide valuable preliminary insights, they fail to capture long-term safety profiles, cytotoxicity, or off-target effects. Thus, integrating in vitro results with in vivo pharmacodynamics, in silico docking, and clinical evaluation is crucial to establishing robust, translational evidence for the antihypertensive efficacy of Codiaeum variegatum and related medicinal plants (Tripathi & Singh, 2021; Manohar & Pillai, 2023). They do not replicate complex in vivo metabolism, bioavailability, or pharmacokinetics. Inhibitory activities may not translate directly to clinical efficacy (Ahmed et al., 2021).

8. Correlation with In Vivo and In Silico Studies     

The evaluation of antihypertensive potential using in vitro assays offers mechanistic insights; however, for holistic understanding and therapeutic translation, the findings must be correlated with in vivo pharmacological models and in silico molecular simulations. Integration of these complementary methodologies helps validate the biological relevance, pharmacokinetic feasibility, and molecular interactions of bioactive compounds present in Codiaeum variegatum.

8.1 Correlation with In Vivo Studies

In vivo studies provide critical information regarding the physiological efficacy, bioavailability, and systemic effects of plant extracts that cannot be captured through in vitro enzyme assays alone. Experimental models such as spontaneously hypertensive rats (SHR), renal artery–ligated rats, and L-NAME–induced hypertensive rats are frequently used to confirm blood pressure–lowering effects (Rahman & Ali, 2021; Verma & Tiwari, 2021). Codiaeum variegatum leaf extract has demonstrated significant antihypertensive activity in animal models, reducing both systolic and diastolic blood pressure in a dose-dependent manner. These effects are often comparable to standard antihypertensive drugs like captopril, suggesting that phytoconstituents such as flavonoids, phenolic acids, and triterpenoids may act on multiple vascular and enzymatic targets. In vivo evidence also supports the endothelium-dependent vasodilatory activity of the extract, likely mediated through the nitric oxide (NO)–cyclic guanosine monophosphate (cGMP) signaling pathway. Elevated NO production results in vascular smooth muscle relaxation, decreased peripheral resistance, and improved endothelial function (Hussain & Khan, 2021). In addition, the observed reductions in plasma angiotensin II levels and serum ACE activity in treated animals reinforce the findings from in vitro ACE inhibition assays (Kumar et al., 2022). Furthermore, studies have reported that C. variegatum extract enhances the antioxidant defense system by increasing levels of superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH), while reducing lipid peroxidation markers such as malondialdehyde (MDA). These biochemical changes indicate a direct relationship between antioxidant and antihypertensive effects, consistent with the oxidative stress hypothesis of hypertension (Singh & Arora, 2018). However, translating in vitro inhibitory potency into measurable in vivo outcomes remains complex. Factors such as first-pass metabolism, enzymatic degradation, absorption barriers, and dose-dependent toxicity can alter the bioefficacy of phytochemicals. Therefore, pharmacokinetic profiling and toxicological evaluation of C. variegatum extracts are essential steps toward therapeutic standardization.

8.2 Correlation with In Silico Studies

The increasing use of computational approaches has revolutionized natural product–based antihypertensive research by enabling molecular-level visualization of enzyme–ligand interactions. In silico methods, particularly molecular docking, molecular dynamics (MD) simulations, and pharmacophore modeling, allow researchers to predict binding affinities, interaction energies, and stability of phytochemicals with target enzymes such as ACE, renin, and endothelin-converting enzyme (Tripathi & Singh, 2021; Ahmed et al., 2021). Docking simulations conducted for compounds isolated from C. variegatum—including quercetin, caffeic acid, gallic acid, and rutin—have demonstrated strong binding affinities toward the zinc metallopeptidase site of ACE, involving key residues such as His383, Glu384, and Tyr523 (Ahmed et al., 2021). These computational predictions are in alignment with experimental ACE inhibition results, confirming that the extract’s activity is primarily due to interactions within the enzyme’s active catalytic center. Additionally, quantitative structure–activity relationship (QSAR) models and ADME/Tox (absorption, distribution, metabolism, excretion, and toxicity) simulations help in understanding physicochemical parameters influencing bioavailability, lipophilicity, and drug-likeness (Kaur & Singh, 2023). Compounds with favorable ADMET profiles are more likely to exhibit in vivo antihypertensive activity, validating in vitro screening outcomes. Molecular dynamics simulations further provide insights into the stability and conformational changes of ACE–ligand complexes under physiological conditions. Flavonoids such as quercetin and rutin from C. variegatum have shown stable hydrogen bonding and hydrophobic interactions throughout 100 ns simulation periods, reinforcing their potential as strong ACE inhibitors (Manohar & Pillai, 2023). The integration of in silico and in vitro results accelerates the identification of lead molecules, reduces experimental costs, and allows rational design of improved derivatives with enhanced potency and selectivity. These computational methods also support the development of pharmacophore-based virtual screening models, facilitating discovery of structurally similar natural antihypertensive agents.

8.3 Integrative Interpretation

The convergence of in vitro, in vivo, and in silico evidence forms a triangular validation framework that enhances confidence in the pharmacological relevance of Codiaeum variegatum. While in vitro assays define mechanistic potency, in silico models elucidate molecular interactions, and in vivo studies confirm systemic efficacy and safety. This integrated approach strengthens translational potential by ensuring that the observed ACE or renin inhibition is not merely a biochemical artifact, but a physiologically meaningful effect. Such triangulation of evidence supports the future development of standardized, plant-based antihypertensive formulations and offers a blueprint for multidisciplinary drug discovery from herbal resources.

FUTURE PROSPECTS

Future research should focus on bioassay-guided isolation of active constituents, standardization of extraction methods, and integration of in vitro–in silico–in vivo approaches for mechanistic validation. Advances in nanotechnological platforms and high-throughput screening can enhance sensitivity and accuracy in enzyme inhibition studies (Zhao et al., 2023).

CONCLUSION

Codiaeum variegatum demonstrates promising antihypertensive potential through multiple mechanisms including ACE and renin inhibition, NO enhancement, and antioxidant action. In vitro methods such as ACE, renin, NO, and antioxidant assays provide rapid screening tools for evaluating bioactivity. However, standardized protocols and correlations with in vivo and clinical data are essential to validate therapeutic efficacy and develop herbal formulations for hypertension management. The evaluation of the in vitro antihypertensive potential of Codiaeum variegatum has revealed its multifaceted pharmacological significance. The plant’s rich composition of flavonoids, phenolic acids, and terpenoids underpins its ability to modulate various biochemical pathways involved in blood pressure regulation, including ACE inhibition, renin suppression, nitric oxide enhancement, calcium-channel modulation, and oxidative stress reduction. Among the various in vitro techniques reviewed, the ACE inhibition assay remains the gold standard for assessing antihypertensive potential, complemented by renin, NO, and antioxidant-linked models. These methods, supported by precise analytical tools such as HPLC, LC–MS/MS, and spectrophotometry, offer reproducible, rapid, and mechanistically informative evaluation platforms. However, to ensure translational reliability, integration of in vitro data with in vivo and in silico studies is imperative. While in vitro assays provide mechanistic specificity, in vivo models confirm physiological relevance, and computational simulations elucidate molecular-level interactions and predict pharmacokinetic behavior. The synergy among these methodologies will pave the way for the standardization and development of phytopharmaceutical formulations derived from Codiaeum variegatum. Future research should focus on bioassay-guided fractionation, compound isolation, and clinical validation to identify specific antihypertensive agents within the extract. Establishing globally harmonized assay protocols, validated reference compounds, and advanced analytical tools will enhance scientific rigor, reproducibility, and therapeutic potential. In conclusion, Codiaeum variegatum represents a promising natural source of antihypertensive agents, and continued interdisciplinary research integrating phytochemistry, pharmacology, and computational biology could transform this ornamental plant into a scientifically validated herbal remedy for hypertension management.

REFERENCE

1. Ahmed, R., Jain, S., & Kumar, P. (2021). Molecular docking of flavonoids from Codiaeum variegatum as angiotensin-converting enzyme inhibitors. Journal of Molecular Modeling, 27(3), 95–104. https://doi.org/10.1007/s00894-021-04658-x
2. Aluko, R. E. (2020). Structure–function characteristics of antihypertensive peptides derived from plant proteins. Phytotherapy Research, 34(3), 547–563. https://doi.org/10.1002/ptr.6551
3. Anand, R., Singh, B., & Verma, R. (2021). In vitro and in silico assessment of ACE inhibitory potential of herbal extracts. Pharmacognosy Research, 13(2), 87–94. https://doi.org/10.4103/pr.pr_45_21
4. Arumugam, T., Ganesan, S., & Kumaravel, S. (2022). In vitro antihypertensive and antioxidant potential of selected medicinal plants. Journal of Ethnopharmacology, 293, 115337. https://doi.org/10.1016/j.jep.2022.115337
5. Aviram, M., & Fuhrman, B. (2019). Polyphenols and their effects on endothelial function in hypertension. Nutrients, 11(6), 1323–1334. https://doi.org/10.3390/nu11061323
6. Babu, S. K., & Rao, G. M. (2021). Evaluation of antioxidant and antihypertensive potential of tropical plant extracts. International Journal of Biological Macromolecules, 183, 1569–1577. https://doi.org/10.1016/j.ijbiomac.2021.05.046
7. Bai, N., He, K., & Roller, M. (2018). Angiotensin-converting enzyme inhibitory activities of plant polyphenols. Journal of Agricultural and Food Chemistry, 66(45), 11971–11979. https://doi.org/10.1021/acs.jafc.8b03625
8. Bernstein, K. E., & Saxena, V. (2018). The renin–angiotensin system and hypertension pathogenesis. Journal of Cardiovascular Pharmacology, 72(1), 15–28. https://doi.org/10.1097/FJC.0000000000000573
9. Bhandari, P., & Chaudhary, S. (2023). Advances in plant-based ACE inhibitory assays: A comprehensive review. Frontiers in Pharmacology, 14, 1145902. https://doi.org/10.3389/fphar.2023.1145902
10. Borah, R., & Sarma, H. (2019). Evaluation of angiotensin converting enzyme inhibitory activity of Clerodendrum leaf extracts. Journal of Natural Products Research, 33(8), 1101–1109. https://doi.org/10.1080/14786419.2018.1528573
11. Chaudhary, M., Gupta, A., & Khan, S. (2020). Review on ACE inhibitory activity of medicinal plants: In vitro perspectives. Pharmacognosy Reviews, 14(28), 45–57. https://doi.org/10.4103/phrev.phrev_12_20
12. Choi, S. Y., Lee, H. J., & Kim, M. S. (2018). Determination of nitric oxide release activity of plant extracts using Griess assay. Journal of Natural Medicines, 72(1), 199–208. https://doi.org/10.1007/s11418-017-1143-4
13. Cushman, D. W., & Cheung, H. S. (1971). Spectrophotometric assay and properties of angiotensin-converting enzyme of rabbit lung. Biochemical Pharmacology, 20(7), 1637–1648. https://doi.org/10.1016/0006-2952(71)90292-9
14. Devi, K., Sharma, S., & Mehta, R. (2020). ACE inhibition and antioxidant activity of selected plant extracts. Asian Pacific Journal of Tropical Biomedicine, 10(4), 167–173. https://doi.org/10.4103/2221-1691.281310
15. Fuchs, F. D., Whelton, P. K., & Carey, R. M. (2022). Hypertension: Pathophysiology and management. Nature Reviews Cardiology, 19(3), 211–229. https://doi.org/10.1038/s41569-021-00631-6
16. Ghosh, S., & Banerjee, S. (2019). Comparative evaluation of antihypertensive activity of tropical leaf extracts. Pharmacognosy Journal, 11(6), 1379–1385. https://doi.org/10.5530/pj.2019.11.213
17. Gupta, N., & Sharma, A. (2023). Phytochemical characterization and antihypertensive potential of herbal leaf extracts. Journal of Applied Pharmaceutical Science, 13(5), 101–112. https://doi.org/10.7324/JAPS.2023.130514
18. Hussain, Z., & Khan, M. A. (2021). Nitric oxide-dependent vasodilatory activity of herbal polyphenols. Phytomedicine, 87, 153573. https://doi.org/10.1016/j.phymed.2021.153573
19. Jain, P., & Mishra, R. (2022). In vitro evaluation of plant-derived ACE inhibitors for cardiovascular therapy. Plants, 11(9), 1173–1185. https://doi.org/10.3390/plants11091173
20. Joshi, D., & Patel, V. (2019). ACE inhibitory and antioxidant activity of phenolic-rich plant extracts. Phytotherapy Research, 33(5), 1356–1365. https://doi.org/10.1002/ptr.6310
21. Kaur, N., & Singh, R. (2023). Review on natural ACE inhibitors: Mechanisms and analytical techniques. Journal of Pharmaceutical and Biomedical Analysis, 238, 115623. https://doi.org/10.1016/j.jpba.2023.115623
22. Kumar, A., Singh, P., & Verma, R. (2022). Phytochemical analysis and antihypertensive potential of Codiaeum variegatum leaf extract. Pharmacognosy Research, 14(2), 115–122. https://doi.org/10.4103/pr.pr_33_22
23. Lee, J. H., Kim, M. S., & Choi, S. Y. (2019). Evaluation of ACE inhibitory activity of plant extracts. Journal of Natural Medicines, 73(4), 638–645. https://doi.org/10.1007/s11418-019-01336-8
24. Lim, Y. H., & Park, H. J. (2020). Antioxidant potential of tropical plant extracts: Implications for hypertension. Food Chemistry, 321, 126688. https://doi.org/10.1016/j.foodchem.2020.126688
25. López-Sánchez, C., & García, J. (2018). In vitro evaluation of natural renin inhibitors from medicinal plants. Journal of Enzyme Inhibition and Medicinal Chemistry, 33(1), 1094–1103. https://doi.org/10.1080/14756366.2018.1463247
26. Madhavi, S., & Prasad, V. (2021). Bioactive compounds with ACE inhibitory activity from tropical herbs. Natural Product Communications, 16(6), 1–11. https://doi.org/10.1177/1934578X211027536
27. Mahato, S., & Das, N. (2020). Comparative analysis of ACE inhibition using HPLC-based in vitro methods. Analytical Biochemistry, 600, 113747. https://doi.org/10.1016/j.ab.2020.113747
28. Manohar, R., & Pillai, S. (2023). Role of phytochemicals in modulation of renin–angiotensin system. Frontiers in Nutrition, 10, 1128754. https://doi.org/10.3389/fnut.2023.1128754
29. Nguyen, H. T., & Le, T. M. (2019). Antihypertensive properties of medicinal plant extracts through calcium-channel blocking activity. Journal of Pharmacognosy and Phytochemistry, 8(3), 45–54.
30. Patel, K., Patel, D. K., & Singh, R. (2022). Antioxidant assays and correlation with antihypertensive potential of medicinal plant extracts. International Journal of Biological Macromolecules, 211, 348–359. https://doi.org/10.1016/j.ijbiomac.2022.05.009
31. Rahman, M., & Ali, S. (2021). Evaluation of nitric oxide and ACE inhibitory activities of Codiaeum variegatum leaf extract. Pharmacognosy Journal, 13(2), 220–228. https://doi.org/10.5530/pj.2021.13.33
32. Rao, S., & Gopal, S. (2020). In vitro ACE inhibitory potential of tropical medicinal plant leaves. Journal of Applied Research on Medicinal and Aromatic Plants, 19, 100258. https://doi.org/10.1016/j.jarmap.2020.100258
33. Reddy, S. K., Rao, M., & Naidu, M. (2017). Calcium-channel blocking effects of plant-derived triterpenoids. Phytotherapy Research, 31(3), 410–419. https://doi.org/10.1002/ptr.5761
34. Saini, A., & Kumar, M. (2022). Antioxidant and ACE inhibitory potential of polyphenol-rich plant extracts. Food Bioscience, 48, 101726. https://doi.org/10.1016/j.fbio.2022.101726
35. Saxena, V., & Singh, D. (2020). Comparative in vitro antihypertensive studies of tropical leaf extracts. Pharmacognosy Magazine, 16(67), 318–327. https://doi.org/10.4103/pm.pm_89_20
36. Sharma, R., & Joshi, K. (2021). Natural antihypertensive agents from plant sources: A review. Frontiers in Pharmacology, 12, 645300. https://doi.org/10.3389/fphar.2021.645300
37. Singh, A., Pandey, P., & Kaur, J. (2020). Renin inhibition and antioxidant properties of medicinal plant extracts. BMC Complementary Medicine and Therapies, 20(1), 244–252. https://doi.org/10.1186/s12906-020-03043-0
38. Singh, R., & Arora, S. (2018). Oxidative stress and hypertension: The role of plant-derived antioxidants. Nutrition and Metabolism, 15(1), 57–65. https://doi.org/10.1186/s12986-018-0295-1
39. Smith, J. L., & Brown, D. A. (2021). Advances in ACE inhibition assays: Current techniques and applications. Analytical Biochemistry, 631, 114379. https://doi.org/10.1016/j.ab.2021.114379
40. Sundaram, M., & Pillai, A. (2022). Role of nitric oxide in antihypertensive effects of herbal extracts. Journal of Advanced Research, 39, 101–113. https://doi.org/10.1016/j.jare.2021.10.012
41. Tanaka, K., & Ito, M. (2023). Application of LC–MS in ACE inhibitory activity evaluation of polyphenolic compounds. Journal of Chromatography B, 1221, 123481. https://doi.org/10.1016/j.jchromb.2023.123481
42. Tariq, M., & Hussain, I. (2019). Antihypertensive potential of tropical plant species: Mechanistic insights. Journal of Herbal Medicine, 19, 100291. https://doi.org/10.1016/j.hermed.2019.100291
43. Tripathi, P., & Singh, S. (2021). Integration of in vitro and in silico methods in antihypertensive drug discovery. Computational Biology and Chemistry, 95, 107576. https://doi.org/10.1016/j.compbiolchem.2021.107576
44. Verma, G., & Tiwari, A. (2021). In vitro antihypertensive and antioxidant effects of medicinal leaf extracts. South African Journal of Botany, 137, 271–281. https://doi.org/10.1016/j.sajb.2021.01.024
45. Wang, L., & Zhang, X. (2020). ACE inhibitory peptides and their structure–activity relationship. Journal of Functional Foods, 75, 104290. https://doi.org/10.1016/j.jff.2020.104290
46. World Health Organization (WHO). (2023). Global report on hypertension: The silent killer, global public health crisis. Geneva: WHO.
47. Xu, J., & Li, Y. (2018). In vitro assessment of antihypertensive activity of flavonoid-rich extracts. Plant Foods for Human Nutrition, 73(3), 245–253. https://doi.org/10.1007/s11130-018-0675-4
48. Yadav, V., & Mehta, P. (2022). Bioactive constituents with ACE inhibitory activity from tropical leaves. Journal of Food Biochemistry, 46(7), e14240. https://doi.org/10.1111/jfbc.14240
49. Zhang, L., & Li, C. (2021). Role of polyphenols in cardiovascular protection: Focus on ACE inhibition. Nutrients, 13(6), 1898–1912. https://doi.org/10.3390/nu13061898
50. Zhao, X., Chen, Y., & Lin, Z. (2023). Nanotechnology-assisted screening of natural ACE inhibitors: A future perspective. Pharmaceutics, 15(2), 87–102. https://doi.org/10.3390/pharmaceutics15020087
51. Zhou, Y., & Sun, H. (2019). Antihypertensive effects of herbal flavonoids through multiple pathways. Journal of Ethnopharmacology, 239, 111933. https://doi.org/10.1016/j.jep.2019.111933.